Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Summaries of opinion Remove Summaries of opinion filter Paediatric investigation plans Remove Paediatric investigation plans filter Withdrawn applications (58) Apply Withdrawn applications filter Orphan designations (259) Apply Orphan designations filter Referrals (1) Apply Referrals filter Direct healthcare professional communication (11) Apply Direct healthcare professional communication filter

Product number

Authorisation status

Authorised (222) Apply Authorised filter Refused (19) Apply Refused filter Withdrawn (16) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Opinion status

Negative (1) Apply Negative filter Positive (17) Apply Positive filter

Application type

Initial authorisation (12) Apply Initial authorisation filter Post-authorisation (6) Apply Post-authorisation filter

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (13) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (73) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (12) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (20) Apply Yes filter

Compliance procedure number

Medicine type

Biosimilar Remove Biosimilar filter Orphan medicine Remove Orphan medicine filter Accelerated assessment (84) Apply Accelerated assessment filter Additional monitoring (586) Apply Additional monitoring filter Conditional approval (82) Apply Conditional approval filter Exceptional circumstances (63) Apply Exceptional circumstances filter Generic (299) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

375 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion Remove Summaries of opinion filter

Categories Human Remove Human filter

Medicine type Orphan medicine Remove Orphan medicine filter Biosimilar Remove Biosimilar filter

Sort by

List item

Human medicine European public assessment report (EPAR): Holoclar (updated)

ex vivo expanded autologous human corneal epithelial cells containing stem cells, Stem Cell Transplantation; Corneal Diseases
Date of authorisation: 17/02/2015, , , , Revision: 10, Authorised, Last updated: 24/11/2023
List item

Human medicine European public assessment report (EPAR): Blincyto (updated)

blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015, , , Revision: 18, Authorised, Last updated: 24/11/2023
List item

Human medicine European public assessment report (EPAR): Symkevi (updated)

tezacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 31/10/2018, , Revision: 12, Authorised, Last updated: 24/11/2023
List item

Human medicine European public assessment report (EPAR): Talvey (updated)

talquetamab, Multiple Myeloma
Date of authorisation: 21/08/2023, , , , Revision: 1, Authorised, Last updated: 24/11/2023
List item

Human medicine European public assessment report (EPAR): Voxzogo (updated)

Vosoritide, Achondroplasia
Date of authorisation: 26/08/2021, , , Revision: 4, Authorised, Last updated: 24/11/2023
List item

Human medicine European public assessment report (EPAR): Herwenda (updated)

trastuzumab, Breast Neoplasms; Stomach Neoplasms
Date of authorisation: 15/11/2023, , , Authorised, Last updated: 23/11/2023
List item

Human medicine European public assessment report (EPAR): Takhzyro (updated)

lanadelumab, Angioedemas, Hereditary
Date of authorisation: 22/11/2018, , , Revision: 12, Authorised, Last updated: 22/11/2023
List item

Human medicine European public assessment report (EPAR): Epoetin Alfa Hexal (updated)

epoetin alfa, Anemia; Kidney Failure, Chronic; Cancer
Date of authorisation: 27/08/2007, , Revision: 24, Authorised, Last updated: 21/11/2023
List item

Human medicine European public assessment report (EPAR): Binocrit (updated)

epoetin alfa, Anemia; Kidney Failure, Chronic
Date of authorisation: 28/08/2007, , Revision: 22, Authorised, Last updated: 21/11/2023
List item

Human medicine European public assessment report (EPAR): Ninlaro (updated)

ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016, , Revision: 17, Authorised, Last updated: 21/11/2023
List item

Human medicine European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos) (updated)

daunorubicin hydrochloride, cytarabine, Leukemia, Myeloid, Acute
Date of authorisation: 23/08/2018, , Revision: 9, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Vimizim (updated)

recombinant human n-acetylgalactosamine-6-sulfatase, Mucopolysaccharidosis IV
Date of authorisation: 27/04/2014, , , Revision: 13, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Darzalex (updated)

Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016, , , Revision: 21, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Fulphila (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 20/11/2018, , Revision: 11, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Wakix (updated)

pitolisant, Narcolepsy
Date of authorisation: 31/03/2016, , , Revision: 15, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Gazyvaro (updated)

Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014, , , Revision: 16, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Tyruko (updated)

natalizumab, Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Date of authorisation: 22/09/2023, , , Revision: 1, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Mylotarg (updated)

gemtuzumab ozogamicin, Leukemia, Myeloid, Acute
Date of authorisation: 19/04/2018, , Revision: 12, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Kauliv (updated)

teriparatide, Osteoporosis; Osteoporosis, Postmenopausal
Date of authorisation: 12/01/2023, , , Revision: 1, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Artesunate Amivas (updated)

artesunate, Malaria
Date of authorisation: 22/11/2021, , , Revision: 4, Authorised, Last updated: 20/11/2023
List item

Human medicine European public assessment report (EPAR): Livmarli (updated)

Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022, , , , Revision: 3, Authorised, Last updated: 13/11/2023
List item

Human medicine European public assessment report (EPAR): Cresemba (updated)

isavuconazole, Aspergillosis
Date of authorisation: 15/10/2015, , Revision: 17, Authorised, Last updated: 13/11/2023
List item

Human medicine European public assessment report (EPAR): Vyvgart (updated)

Efgartigimod alfa, Myasthenia Gravis
Date of authorisation: 10/08/2022, , , Revision: 4, Authorised, Last updated: 09/11/2023
List item

Human medicine European public assessment report (EPAR): Lunsumio (updated)

mosunetuzumab, Lymphoma, Follicular
Date of authorisation: 03/06/2022, , , , Revision: 2, Authorised, Last updated: 09/11/2023
List item

Human medicine European public assessment report (EPAR): Zirabev (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019, , , Revision: 13, Authorised, Last updated: 09/11/2023